Distinct effects of β1 integrin on cell proliferation and cellular signaling in MDA-MB-231 breast cancer cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hou, Sicong ^a   Isaji, Tomoya ^a   Hang, Qinglei ^a   Im, Sanghun ^a   Fukuda, Tomohiko ^a   Gu, Jianguo ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BETA1 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN SUBUNIT; QUINAZOLINE DERIVATIVE; TYRPHOSTIN;

ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMISTRY; DRUG EFFECTS; FEMALE; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN SUBUNIT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIGENS, CD29; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE DELETION; GENE EXPRESSION; GENE KNOCKOUT TECHNIQUES; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN SUBUNITS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TYRPHOSTINS;

EID: 84953227393     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18430     Document Type: Article

References (47)

1. Hynes, R. O. Integrins: Bidirectional, allosteric signaling machines. Cell. 110, 673-687 (2002).
2. Schlaepfer, D. D. & Hunter, T. Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2/mitogenactivated protein kinase through interactions with and activation of c-Src. J Biol Chem. 272, 13189-13195 (1997).
3. Imanishi, Y. et al. Angiopoietin-2 stimulates breast cancer metastasis through the alpha (5) beta (1) integrin-mediated pathway. Cancer Res. 67, 4254-4263 (2007).
4. Jahangiri, A., Aghi, M. K. & Carbonell, W. S. beta1 integrin: Critical path to antiangiogenic therapy resistance and beyond. Cancer Res. 74, 3-7 (2014).
5. Aoudjit, F. & Vuori, K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 20, 4995-5004 (2001).
6. Nistico, P., Di Modugno, F., Spada, S. & Bissell, M. J. beta1 and beta4 integrins: From breast development to clinical practice. Breast Cancer Res. 16, 459 (2014).
7. Wang, F. et al. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: A different perspective in epithelial biology. Proc Natl Acad Sci. USA. 95, 14821-14826 (1998).
8. Park, C. C. et al. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 66, 1526-1535 (2006).
9. Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J. & Bissell, M. J. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 68, 4398-4405 (2008).
10. Howlett, A. R., Bailey, N., Damsky, C., Petersen, O. W. & Bissell, M. J. Cellular growth and survival are mediated by beta 1 integrins in normal human breast epithelium but not in breast carcinoma. J Cell Sci. 108, 1945-1957 (1995).
11. Hughes, P. E. et al. Suppression of integrin activation: A novel function of a Ras/Raf-initiated MAP kinase pathway. Cell. 88, 521-530 (1997).
12. Miranti, C. K. & Brugge, J. S. Sensing the environment: A historical perspective on integrin signal transduction. Nat Cell Biol. 4, E83-90 (2002).
13. Castello-Cros, R., Khan, D. R., Simons, J., Valianou, M. & Cukierman, E. Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer. 9, 94 (2009).
14. Taherian, A., Li, X., Liu, Y. & Haas, T. A. Differences in integrin expression and signaling within human breast cancer cells. BMC Cancer. 11, 293 (2011).
15. Wang, F. et al. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst. 94, 1494-1503 (2002).
16. Werb, Z., Vu, T. H., Rinkenberger, J. L. & Coussens, L. M. Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS. 107, 11-18 (1999).
17. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer. 10, 9-22 (2010).
18. Chen, X. et al. Integrin alpha1beta1 controls reactive oxygen species synthesis by negatively regulating epidermal growth factor receptor-mediated Rac activation. Mol Cell Biol. 27, 3313-3326 (2007).
19. Sieg, D. J. et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2, 249-256 (2000).
20. Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat Protoc. 1, 2315-2319 (2006).
21. Frisch, S. M. & Screaton, R. A. Anoikis mechanisms. Curr Opin Cell Biol. 13, 555-562 (2001).
22. Paez, J. G. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304, 1497-1500 (2004).
23. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350, 2129-2139 (2004).
24. Milanezi, F., Carvalho, S. & Schmitt, F. C. EGFR/HER2 in breast cancer: A biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn. 8, 417-434 (2008).
25. Banerjee, S. et al. Basal-like breast carcinomas: Clinical outcome and response to chemotherapy. J Clin Pathol. 59, 729-735 (2006).
26. Roskoski, R., Jr. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res. 94, 9-25 (2015).
27. Dawson, J. P. et al. Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25, 7734-7742 (2005).
28. Moulder, S. L. et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61, 8887-8895 (2001).
29. Anido, J. et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res. 9, 1274-1283 (2003).
30. Normanno, N. et al. Target-based therapies in breast cancer: Current status and future perspectives. Endocr Relat Cancer. 16, 675-702 (2009).
31. Ellis, A. G. et al. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem Pharmacol. 71, 1422-1434 (2006).
32. Gilcrease, M. Z. et al. Alpha6 beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. J Exp Clin Cancer Res 28, 67 (2009).
33. Zhang, Y. et al. Nuclear SIPA1 activates integrin beta1 promoter and promotes invasion of breast cancer cells. Oncogene. 34, 1451-1462 (2015).
34. Mebratu, Y. & Tesfaigzi, Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle. 8, 1168-1175 (2009).
35. Lesniak, D. et al. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res. 69, 8620-8628 (2009).
36. Huang, C. et al. beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 13, R84, (2011).
37. Eke, I. et al. Simultaneous beta1 integrin-EGFR targeting and radiosensitization of human head and neck cancer. J Natl Cancer Inst. 107, 419 (2015).
38. Ramirez, N. E. et al. The alpha (2) beta (1) integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest. 121, 226-237 (2011).
39. Falcioni, R. et al. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res. 236, 76-85 (1997).
40. Nieto, M. A. & Cano, A. The epithelial-mesenchymal transition under control: Global programs to regulate epithelial plasticity. Semin Cancer Biol. 22, 361-368 (2012).
41. Beaty, B. T. et al. beta1 integrin regulates Arg to promote invadopodial maturation and matrix degradation. Mol Biol Cell. 24, 1661-1675 (2013).
42. Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 137, 231-245 (1997).
43. Margadant, C., Kreft, M., de Groot, D. J., Norman, J. C. & Sonnenberg, A. Distinct roles of talin and kindlin in regulating integrin alpha5beta1 function and trafficking. Curr Biol.CB 22, 1554-1563 (2012).
44. Xu, Q. et al. Roles of N-acetylglucosaminyltransferase III in epithelial-to-mesenchymal transition induced by transforming growth factor beta1 (TGF-beta1) in epithelial cell lines. J Biol Chem. 287, 16563-16574 (2012).
45. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 8, 2281-2308 (2013).
46. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 343, 84-87 (2014).
47. Isaji, T., Sato, Y., Fukuda, T. & Gu, J. N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: Identification of the minimal N-glycosylation requirement for alpha 5 beta1. The J Biol Chem. 284, 12207-12216 (2009).